| IVEVF Stock | | | USD 3.64 0.00 0.00% |
Founder
Dr. Pierre Broqua, Ph.D. serves as CoFounder, Chief Scientific Officer of Inventiva S.A. He brings over 25 years of experience in drug discovery and innovative research to Inventiva. Before cofounding Inventiva, he successfully managed numerous research programs leading to the discovery of highly innovative preclinical and clinical compounds, in particular during his tenure at Ferring Pharmaceuticals from 1997 to 2002 and Fournier Laboratories from 2002 to 2005, as Head of Neuroscience for Solvay Pharmaceuticals from 2007 to 2010 and finally as Head of Research for the Abbott Dijon RD site. One of his most notable achievements was his codiscovery, while head of Pharmacology at Ferring Pharmaceuticals, of the GnRH antagonist Degarelix . He holds a Ph.D. in Pharmacology from the Universite Paris V Rene Descartes and has a Masters degree in Chemistry and Biochemistry from Universite Pierre et Marie Curie.
| Age | 61 |
| Phone | 33 3 80 44 75 00 |
| Web | https://www.inventivapharma.com |
Inventiva Management Efficiency
The company has return on total asset
(ROA) of
(0.3438) % which means that it has lost $0.3438 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(0.7073) %, meaning that it generated substantial loss on money invested by shareholders. Inventiva's management efficiency ratios could be used to measure how well Inventiva manages its routine affairs as well as how well it operates its assets and liabilities.
Inventiva SA has accumulated 8.74
M in total debt with debt to equity ratio
(D/E) of 0.27, which may suggest the company is not taking enough advantage from borrowing. Inventiva SA has a current ratio of 4.08, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Inventiva until it has trouble settling it off, either with new capital or with free cash flow. So, Inventiva's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Inventiva SA sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Inventiva to invest in growth at high rates of return. When we think about Inventiva's use of debt, we should always consider it together with cash and equity.
Similar Executives
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis , mucopolysaccharidoses , and other diseases. Inventiva S.A. was founded in 2011 and is based in Daix, France. Inventiva is traded on OTC Exchange in the United States. Inventiva SA [IVEVF] is a
Pink Sheet which is traded through a dealer network over-the-counter (OTC).
Management Performance
Inventiva SA Leadership Team
Elected by the shareholders, the Inventiva's board of directors comprises two types of representatives: Inventiva inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Inventiva. The board's role is to monitor Inventiva's management team and ensure that shareholders' interests are well served. Inventiva's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Inventiva's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jean Volatier, Chief Officer | |
| Eric LLM, G Counsel | |
| Frederic Cren, CEO, Co-Founder | |
| JeanPaul MD, Head Pharmacovigilance | |
| Michael Cooreman, Chief Officer | |
| Pierre Broqua, Co-Founder, Chief Scientific Officer | |
| Irena Konstantinova, Head of Fibrosis Research | |
| Nathalie Harroy, Head of Human Resources | |
Inventiva Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Inventiva a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Inventiva Pink Sheet
When determining whether Inventiva SA offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Inventiva's
financial statements, including income statements, balance sheets, and cash flow statements, to assess its
financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Inventiva Sa Stock.
Outlined below are crucial reports that will aid in making a well-informed decision on Inventiva Sa Stock: Check out
Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inventiva SA. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in real.
You can also try the
Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Please note, there is a significant difference between Inventiva's value and its price as these two are different measures arrived at by different means. Investors typically determine if Inventiva is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inventiva's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.